Resultados de perda de peso com o Wegovy, mês a mês.

Quick answer: average weight loss on Wegovy

The headline number is 14.9%. That is the mean percentage of body weight lost by adults who took 2.4 mg of semaglutide weekly for 68 weeks in the STEP 1 trial, compared with 2.4% in the placebo group (Source: New England Journal of Medicine, Wilding et al., 2021). Of the 1,961 adults randomized in STEP 1, more than 86% lost at least 5% of their starting weight, around 69% lost at least 10%, around 51% lost at least 15%, and approximately one-third lost 20% or more.

In practical terms, here is what those percentages translate to at common starting weights. These are average figures — your individual result will depend on adherence, dose, diet, activity, sleep, and biology.

What the STEP clinical trials actually showed

The Semaglutide Treatment Effect in People with Obesity (STEP) program is a series of randomized controlled trials run by Novo Nordisk to support FDA approval of Wegovy. Each STEP trial answered a different question. Together they form the strongest body of evidence on what semaglutide does for body weight in adults.

STEP 1 — the headline trial

STEP 1 was a 68-week, double-blind, placebo-controlled trial of 1,961 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition. Participants received either 2.4 mg of semaglutide weekly or matched placebo, plus monthly behavioral counseling. The primary result: 14.9% average body weight loss on semaglutide vs 2.4% on placebo. Waist circumference dropped by an average of 13.5 cm. Cardiometabolic markers — blood pressure, HbA1c, lipids, C-reactive protein — improved across the board.

STEP 3 — semaglutide plus intensive lifestyle therapy

STEP 3 added a structured intensive behavioral intervention (low-calorie meal replacements, regular dietitian visits, prescribed exercise) on top of semaglutide. The 611 adults randomized lost an average of 16.0% of body weight at 68 weeks on semaglutide plus intensive therapy, compared to 5.7% in the placebo plus intensive therapy arm. The takeaway: structured lifestyle support adds a few extra percentage points to the drug effect, but the drug does most of the heavy lifting.

STEP 4 — what happens if you stop

STEP 4 was the maintenance trial. All 803 participants started on semaglutide and titrated up to 2.4 mg over 20 weeks. They were then randomized to continue semaglutide or switch to placebo for the next 48 weeks. The continuers lost an additional 7.9% on top of what they had already lost. The placebo group regained an average of 6.9%. The implication is uncomfortable but clear: stopping the drug largely reverses the benefit, even if behavior stays constant.

STEP 5 — long-term, two-year data

STEP 5 followed 304 adults on semaglutide or placebo for 104 weeks (about two years). The semaglutide group lost 15.2% of body weight at week 104 vs 2.6% on placebo. Crucially, weight loss continued well into the second year for many patients before plateauing, and the safety profile remained consistent with shorter trials. STEP 5 is the strongest published evidence that the result is durable as long as treatment continues.

STEP 8 — head to head against liraglutide (Saxenda)

STEP 8 compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily (Saxenda, the previous-generation GLP-1 from Novo Nordisk) over 68 weeks. Semaglutide produced an average 15.8% body weight loss vs 6.4% for liraglutide. That comparison helped establish semaglutide as the more effective GLP-1 monotherapy for weight management before tirzepatide entered the picture.

For a comparison with the current strongest competitor, see Wegovy vs Zepbound — tirzepatide produced 20.9% average weight loss in the SURMOUNT-1 trial, the highest figure published for any approved obesity medication to date.

Month-by-month timeline: what to expect from week 1 to month 18

Wegovy follows a deliberate dose escalation schedule. The starting dose is intentionally low — 0.25 mg weekly for the first month — to let your body adapt to the GLP-1 effects and minimize nausea. The dose then doubles roughly every four weeks until you reach the maintenance dose of 1.7 mg or 2.4 mg weekly. Weight loss tracks the dose more than it tracks calendar time.

*Ranges are illustrative based on STEP 1 averages for an adult starting at roughly 220-260 lb. Your numbers will be different — usually lower if you start at a lower weight, often higher if you start much heavier.

Weeks 1-4 (0.25 mg starting dose)

The first month is more about adjustment than weight loss. Most patients feel some appetite suppression within 24-72 hours of the first injection — a quieting of "food noise", smaller portion sizes feeling satisfying, less interest in snacking between meals. The scale typically drops 2-5 lb in the first month, though about 15-20% of patients lose nothing at all in this phase. Mild nausea is common during the first week and again briefly at the dose increase to 0.5 mg.

Weeks 5-12 (0.5 mg → 1.0 mg, escalating doses)

This is the phase where most patients realize the drug is working. The dose doubles to 0.5 mg in week 5 and again to 1.0 mg in week 9. Appetite suppression intensifies. Many people start to find that previously appealing foods — desserts, fried food, fast food — become uninteresting or even unpleasant. By the end of week 12, total loss is typically in the 10-15 lb range. The first searches for "wegovy before and after 1 month" and "wegovy before and after 3 months" usually start here.

Weeks 13-16 (1.7 mg)

The fourth dose step. Some patients hold at 1.7 mg as their long-term maintenance dose if they are tolerating it well and losing weight steadily. Others continue up to 2.4 mg. Visible changes — looser clothes, slimmer face, lower numbers on the scale — are obvious to others by this point.

Months 4-6 (2.4 mg maintenance dose)

This is the steepest part of the curve for most people. In STEP 1, weight loss accelerated through the first six months on the full dose. Average loss rates of 1-2 lb per week are common. Many patients see their best month-over-month numbers in this window. Side effects have usually settled. Energy returns once the body adapts to the lower calorie intake.

Months 6-12 (continued loss, slowing)

The rate of loss usually slows in the second half of year one. Where months 4-6 might have produced 4-6 lb per month, months 9-12 might produce 2-3 lb per month. The total loss curve in STEP 1 looks like a slow-bending arc rather than a straight line. Loss is still happening — it is just smaller each week.

Months 12-18 (plateau and maintenance)

Most patients reach their individual setpoint somewhere between month 12 and month 18. The scale stops moving meaningfully. Appetite suppression continues, calorie intake remains lower than before treatment, but the body has adapted to its new weight and the deficit closes. This is the maintenance phase. The goal shifts from losing more to keeping what you have lost. STEP 5 showed this plateau is durable for at least two years on continued treatment.

How quickly does Wegovy start working?

Three different "start working" milestones, three different timelines:

• Appetite suppression: within 1 to 3 days of the first 0.25 mg injection. Many patients describe a sudden quieting of food cravings as the most striking early effect.
• Measurable weight loss on the scale: typically by week 2 or 3, with 2-5 lb gone by the end of week 4 for the average responder.
• Visible body changes: usually around month 2 or 3, when total loss reaches 8-15 lb and clothes start fitting differently.

Pharmacologically, semaglutide reaches steady-state blood levels after about 4-5 weeks of weekly dosing because of its long half-life. That is why dose increases happen on a four-week schedule — your body has time to fully adjust to each step before the next one. The starting dose of 0.25 mg is too low to produce major weight loss; it is a tolerability dose. The "real" weight loss curve starts when the dose escalates to 0.5 mg and beyond.

Why some people lose more than others

Average weight loss in STEP 1 was 14.9%, but the distribution was wide. About a third of participants lost 20% or more. About 14% did not reach the 5% threshold that defines a "clinically meaningful" response. The factors that explain this variation are partly behavioral and partly biological.

Factors that favor a stronger response

• Higher baseline BMI (people starting heavier tend to lose more in absolute pounds)
• Reaching and tolerating the full 2.4 mg dose
• Strong appetite-suppression effect in the first month (an early signal of biological responsiveness)
• High protein intake and resistance training, which preserve lean mass and metabolic rate
• Adequate sleep — chronic sleep restriction blunts weight loss in both medicated and non-medicated trials
• Fewer concurrent medications that promote weight gain

Factors that blunt response

• Holding at a lower dose (0.25-0.5 mg) due to side effects or insurance friction
• Untreated hypothyroidism, PCOS, or Cushing's syndrome
• Antipsychotics, certain antidepressants, insulin, or systemic steroids
• Liquid calorie intake — sodas, juices, sweetened coffee drinks bypass the satiety effect
• Very low protein intake leading to muscle loss without fat loss
• Genetic variants affecting GLP-1 receptor sensitivity (under active research)

The clinical rule of thumb most obesity medicine specialists use: if a patient has not lost at least 5% of body weight after 12-16 weeks on the full maintenance dose, the probability of becoming a responder is low and switching medications is reasonable. Most often that means moving to tirzepatide (Zepbound). Read our Wegovy vs Zepbound comparison for the head-to-head data.

What to do if you are not losing weight on Wegovy

A stalled scale on Wegovy is not unusual, especially in the first few weeks at a new dose or after several months of steady loss. Before concluding that the drug is not working, run through this checklist with your provider.

1. Confirm you are at the maintenance dose

Most weight loss on Wegovy happens at 1.7 mg or 2.4 mg, not at the starting doses. If you are still escalating, the drug has not yet reached its full effect. Hold judgment until you have been at the maintenance dose for at least 12 weeks.

2. Audit liquid calories and sauces

GLP-1 satiety signaling works on stomach distension and post-meal fullness. Liquid calories — soda, juice, sweetened coffee, alcohol, smoothies, creamer — bypass that signal entirely and add up fast. The same is true for high-calorie sauces, dressings, and oils. A 600-calorie latte plus a "small" salad can be more than a 1,000-calorie meal you barely registered.

3. Check protein and resistance training

Without adequate protein (around 1.2-1.6 g per kg of ideal body weight per day) and some resistance training, a portion of any weight loss comes from muscle. Muscle loss reduces resting metabolic rate, which narrows the deficit even though the drug is doing its job. The scale may stall while body composition still improves, or it may stall because the deficit has actually closed.

4. Re-screen for hidden medical issues

Untreated hypothyroidism, polycystic ovary syndrome, sleep apnea, and Cushing's syndrome all blunt weight loss. Several common medications — second-generation antipsychotics, certain mood stabilizers, beta blockers, insulin, and systemic steroids — also drive weight gain or block loss. Ask your provider for a basic re-screen if you have stalled for more than 8-12 weeks at the full dose.

5. Consider whether you have hit your individual setpoint

Some plateaus are real plateaus — you have reached the new equilibrium your body can hold on this dose. That does not mean failure. A 10% loss reduces cardiovascular risk, blood pressure, blood sugar, sleep apnea severity, and joint pain meaningfully. The maintenance phase is the goal, not a problem.

6. Talk to your provider about switching

If you have completed at least 12-16 weeks on 2.4 mg, are adherent, have ruled out the issues above, and have not lost 5% of body weight, the data supports switching to tirzepatide (Zepbound). SURMOUNT-1 produced a 20.9% average loss on tirzepatide, and many people who under-respond to semaglutide respond well to the dual GIP/GLP-1 mechanism.

Keeping weight off after Wegovy — rebound risk

The most uncomfortable finding from the STEP program came from STEP 1's extension and from STEP 4. After participants stopped taking semaglutide, they regained about two-thirds of the weight they had lost within one year. Cardiometabolic improvements — blood pressure, glucose, lipids — also reverted toward baseline. This is not a personal failure or a sign that the drug "stopped working". It is a feature of how obesity behaves as a chronic disease.

The biology behind regain is well understood. Semaglutide reduces appetite by activating GLP-1 receptors in the brain. When you stop the drug, those receptors return to baseline activity, hunger comes back, and gastric emptying speeds up so meals feel less filling. At the same time, the body has adapted to a lower weight by reducing resting metabolic rate slightly, so the calorie deficit you maintained while losing weight is now harder to sustain at the same intake.

Practical implications for keeping weight off:

• Most patients should plan to stay on Wegovy long-term. Obesity medicine guidelines treat it like high blood pressure — a chronic condition managed with ongoing medication.
• If you must stop, taper off by stepping down doses rather than stopping abruptly, build a structured maintenance plan with high protein and regular resistance training, and monitor weight weekly so you can intervene early if regain begins.
• Some patients transition to a lower maintenance dose (1.0 mg or 1.7 mg) rather than fully stopping. This may preserve appetite suppression with less cost and fewer side effects. Ask your provider whether this is an option.
• Strength-trained muscle is the most protective factor against regain in any weight-loss intervention. Two to three resistance sessions per week during and after weight loss protects metabolic rate.

5 evidence-based ways to maximize weight loss on Wegovy

The drug does most of the work. But there is meaningful variation in how much weight people lose at the same dose, and several controllable factors are well supported by clinical data.

1. Reach and stay at the full dose

STEP 1 used 2.4 mg as the target dose because that is the dose with the strongest weight-loss effect in dose-response studies. Many real-world patients hold at 1.0 mg or 1.7 mg because of side effects or insurance hassles, and their average results are correspondingly lower. If side effects are the limiter, talk to your provider about slowing the titration rather than stopping it — extending each dose step from four to six or eight weeks can dramatically improve tolerance.

2. Hit a protein target every day

Aim for 1.2-1.6 grams of protein per kilogram of ideal body weight per day. For most adults that means 80-130 g daily. Protein protects lean muscle mass, maintains resting metabolic rate, and increases satiety. It also reduces the rate of hair loss reported by 3% of trial participants. The lower your appetite goes on Wegovy, the more deliberate you have to be about hitting protein — it does not happen by accident on small portions.

3. Add resistance training, even briefly

Two to three short resistance sessions per week (30-45 minutes each) is enough to preserve muscle mass during weight loss. Bodyweight, dumbbells, and machines all work. Cardio is fine for cardiovascular health but does not protect muscle the way resistance training does. The combination of GLP-1 medication + protein + resistance training is the most muscle-sparing weight loss approach published to date.

4. Cut liquid calories aggressively

GLP-1 satiety works on stomach distension. Liquid calories largely bypass it. Eliminating sweetened drinks, juices, and high-calorie coffee orders is one of the highest-leverage changes you can make on Wegovy, because it costs you nothing in terms of fullness or enjoyment of meals.

5. Sleep, stress, and timing

Chronic sleep restriction (less than 6.5 hours) blunts weight loss in both pharmacological and behavioral trials. So does chronically elevated cortisol from unmanaged stress. Aim for 7-8 hours of sleep, manage stress proactively, and front-load calories earlier in the day if possible — late-night eating undermines glucose control even at the same calorie intake.

For a deeper food guide, see the Wegovy diet plan. For full dose timing and titration details, see the Wegovy dosing guide.

"Wegovy face" and aesthetic changes to expect

The phrase "Wegovy face" entered the public conversation in 2023, when celebrities and journalists began noticing that rapid GLP-1 weight loss often produces visible changes in the face — slimmer cheeks, more prominent cheekbones, hollowing under the eyes, and looser skin around the jaw. It is not a side effect of the drug per se. It is the predictable consequence of losing subcutaneous fat in the face, which happens with any major weight loss whether it is from surgery, diet, or medication.

Why it stands out with Wegovy specifically is that the loss is faster and larger than most patients have ever experienced before. A 30-pound loss over 6 months produces more visible facial change than the same 30-pound loss over 3 years.

What helps minimize "Wegovy face"

• Slower titration — staying longer at each dose stretches out the rate of loss and gives skin more time to retract.
• Adequate protein — at least 1.2 g/kg/day. Collagen synthesis and skin elasticity depend on amino acid availability.
• Resistance training — preserves overall lean mass, reduces the proportion of weight that comes from facial fat depots vs other tissue.
• Hydration — chronic mild dehydration emphasizes facial volume loss.
• Sun protection — UV damage compounds skin aging that becomes visible after fat loss.
• Dermatology options once weight stabilizes — fillers, microneedling, radiofrequency. Discuss with a board-certified dermatologist after at least 3-6 months of stable weight.

We cover the broader skin and aesthetic angle, including hair loss, in the Wegovy side effects guide.

Real-world results vs clinical trials

STEP 1 produced a clean 14.9% average. Real-world results are usually lower. A retrospective cohort study of more than 2,400 adults on semaglutide for at least 12 months, published in Obesity in 2024, found average weight loss of about 8-12% — still substantial, but meaningfully below the trial figure.

Why the gap exists:

• Adherence. Trial participants get free medication, monthly check-ins, and structured behavioral support. Real-world patients face cost, insurance friction, supply shortages, and side effects with less coaching to push through them.
• Dose held below 2.4 mg. A meaningful share of real-world patients stay on 1.0 mg or 1.7 mg as their effective maintenance dose because of side effects or insurance limits. Dose-response data clearly shows lower doses produce smaller losses.
• Follow-up is shorter. STEP 1 ran 68 weeks. Many real-world studies look at 6-12 months, before patients have reached their full loss curve.
• Less structured behavioral support. Trial participants got monthly counseling and a calorie target. Real-world patients usually do not.

The honest framing for new patients: plan for 8-12% loss as a realistic average, with a real possibility of 14-18% if everything goes well, and a smaller chance of less than 5% if you turn out to be a non-responder.

Before and after — what is and is not realistic

A search for "wegovy before and after" returns thousands of social media transformations. Some are real, many are cherry-picked, and a few are heavily edited or unrelated to the drug. The realistic picture is more measured.

What is realistic

• 10-15% body weight loss over 12-18 months on the full maintenance dose, with good adherence
• Visibly looser clothing by month 3-4
• Slimmer face by month 4-6
• Improved energy after the initial GI side effects fade
• Lower blood pressure, better blood sugar, improved sleep apnea
• Reduced "food noise" and snacking — often described as the most life-changing effect

What is not realistic

• Losing 50 lb in 3 months (would require an extreme deficit and is rarely seen in trials)
• Permanent results without ongoing treatment — most regain about two-thirds within a year of stopping
• Spot fat reduction from specific body areas — fat loss is global
• Six-pack abs without resistance training — fat loss alone does not build visible muscle
• Identical results to a celebrity or influencer — they are usually paired with personal trainers, dietitians, dermatologists, and sometimes additional procedures

The most useful comparison is to your own baseline numbers, not other people's photos. Track weight weekly (same time, same conditions), waist circumference monthly, blood pressure and labs every 3-6 months, and how you feel day to day. That is what tells you whether the drug is working for you.

Wegovy success stories: how to read them critically

Patient testimonials and "success stories" are among the most-searched Wegovy content online. They are useful for normalization — knowing other people have been through the same titration and had similar side effects can be reassuring — but they have well-documented selection bias. People who respond well are far more likely to share their story than people who do not respond, drop out, or regain. The same is true of every weight-loss intervention from surgery to keto.

When reading reviews and stories, look for specifics: starting weight, current weight, how long on the drug, current dose, side effects experienced, lifestyle changes alongside the medication, and whether the person has reached a plateau yet. A "I lost 60 lb on Wegovy" headline is hard to interpret without the denominator (starting weight) and the timeline. The clinical trial averages are more reliable as a baseline expectation than any single anecdote.

Frequently Asked Questions

Quanto peso se pode perder com o Wegovy?

No ensaio clínico STEP 1, os adultos com a dose semanal completa de 2.4 mg perderam, em média, 14.9% do seu peso corporal ao longo de 68 semanas, contra 2.4% no grupo de placebo. Cerca de um terço dos participantes perdeu 20% ou mais do peso corporal inicial. Para alguém que pesa 220 lb (100 kg), 14.9% correspondem a cerca de 33 lb. Os resultados no mundo real são normalmente inferiores às médias dos ensaios, porque a adesão é mais difícil fora de um estudo estruturado.

Com que rapidez o Wegovy começa a fazer efeito?

A maioria dos doentes nota a redução do apetite nos primeiros dias após a primeira injeção de 0.25 mg, embora essa dose inicial seja demasiado baixa para uma perda de peso substancial por si só. A perda de peso mensurável costuma surgir entre a semana 2 e a 4, com 2-5 lb perdidas no primeiro mês para quem responde de forma típica. O ritmo acelera à medida que a dose aumenta, e a taxa de perda mais acentuada ocorre normalmente entre o mês 3 e o 9 na dose de manutenção de 1.7 mg ou 2.4 mg.

Quanto tempo demora a ver resultados com o Wegovy?

As alterações do apetite surgem em dias. As alterações na balança surgem em semanas. As alterações corporais visíveis (roupa mais folgada, rosto mais fino) costumam surgir por volta do mês 2 ou 3. O ensaio STEP 1 mostrou a perda de peso a continuar de forma constante até cerca da semana 60, antes de se aproximar de uma estagnação. A maioria dos doentes deve dar ao Wegovy pelo menos 12 a 16 semanas na dose-alvo antes de avaliar se está a resultar.

Porque é que não estou a perder peso com o Wegovy?

As razões comuns incluem ainda não estar na dose de manutenção (a perda acelera depois de concluído o aumento gradual), repor o défice calórico através de calorias líquidas ou de snacks, problemas médicos ocultos como hipotiroidismo não tratado ou SOP, certos medicamentos que promovem o aumento de peso, sono insuficiente e uma ingestão de proteína muito baixa que leva à perda de músculo sem perda de gordura. Cerca de 10-15% dos doentes são não respondedores biológicos e perdem menos de 5% do peso corporal mesmo com adesão total.

Continua-se a perder peso na dose de manutenção do Wegovy?

Sim, para a maioria das pessoas. A dose de manutenção (1.7 mg ou 2.4 mg por semana) é quando ocorre a parte mais acentuada da curva de perda de peso. No STEP 1, a perda de peso média continuou desde o mês 5 até cerca do mês 14, antes de estabilizar. A perda não para no momento em que se atinge a dose-alvo — é normalmente aí que acelera.

O que acontece quando se deixa de tomar o Wegovy?

Os dados clínicos do ensaio de extensão do STEP 1 mostraram que os participantes que interromperam o semaglutido recuperaram cerca de dois terços do peso que tinham perdido no prazo de um ano após a interrupção. O apetite regressa em dias a semanas, o esvaziamento gástrico volta a acelerar e as adaptações metabólicas ocorridas durante a perda de peso favorecem a recuperação. As orientações da medicina da obesidade tratam isto como uma condição crónica e recomendam tratamento a longo prazo para os doentes que o toleram e continuam a beneficiar.

Quanto tempo o Wegovy permanece no organismo?

O semaglutido tem uma semivida de cerca de uma semana. Após a última injeção, os níveis do medicamento diminuem para metade a cada semana, e demora cerca de 5 a 7 semanas até se considerar que o medicamento foi totalmente eliminado do corpo. A supressão do apetite costuma desvanecer-se no prazo de 2 a 4 semanas após a interrupção, bastante antes de o medicamento se tornar indetetável.

O que é o "rosto Wegovy"?

O "rosto Wegovy" é um termo mediático para a perda de volume facial que algumas pessoas notam com a perda de peso rápida. Não é um efeito direto do medicamento — é a consequência previsível da perda de gordura subcutânea nas bochechas, nas têmporas e à volta do maxilar. Uma perda de peso mais lenta, uma ingestão adequada de proteína, o treino de força e uma boa hidratação podem todos ajudar a minimizar o aspeto. Para alguns, os tratamentos de dermatologia podem ser apropriados assim que o peso estabilizar.

A perda de peso com o Wegovy é permanente?

A perda de peso mantém-se enquanto o tratamento continuar. O ensaio STEP 4 demonstrou que os doentes que continuaram o semaglutido continuaram a perder peso, enquanto os que passaram para placebo recuperaram de forma constante. Não há evidência de que o Wegovy "reponha" permanentemente o ponto de referência do peso corporal. A maioria dos clínicos trata a obesidade como a hipertensão: uma condição crónica que responde a tratamento contínuo.

Como se compara a perda de peso com o Wegovy no mundo real com os ensaios clínicos?

Os estudos no mundo real publicados em 2023 e 2024 mostram, de modo geral, uma perda de peso média inferior à dos ensaios STEP. Uma análise retrospetiva de mais de 2.400 adultos a tomar semaglutido durante pelo menos um ano encontrou uma perda de peso média de 8 a 12% — significativamente inferior à média de 14.9% dos ensaios. Os principais fatores são a menor adesão, as taxas mais elevadas de manutenção da dose devido a efeitos secundários e um apoio nutricional menos estruturado do que o que os participantes dos ensaios receberam.

O Wegovy funciona para toda a gente?

Nenhum medicamento funciona para toda a gente. No STEP 1, cerca de 86% dos participantes com 2.4 mg perderam pelo menos 5% do peso corporal, mas aproximadamente 14% não. Os fatores genéticos, o perfil de hormonas intestinais, a resistência à insulina de base e os fatores comportamentais desempenham todos um papel. A maioria dos profissionais considera uma perda de 5% às 12-16 semanas na dose de manutenção um limiar razoável para um respondedor; abaixo disso, mudar de medicamento (muitas vezes para tirzepatido) é um passo seguinte comum.

É possível criar tolerância ao Wegovy ao longo do tempo?

Não há evidência forte de verdadeira tolerância farmacológica ao semaglutido. A estagnação que a maioria das pessoas atinge entre o mês 12 e o 18 explica-se melhor pela adaptação metabólica — o corpo torna-se mais eficiente com um peso corporal mais baixo, as necessidades calóricas descem e a diferença entre a ingestão e o gasto estreita-se. A dose de manutenção continua a suprimir o apetite mesmo depois de a balança parar de descer, e é por isso que interromper o medicamento leva normalmente à recuperação do peso.